In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 471-472

  Nguyen, M Hong ^a   Yu, Christine Y ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, MICROBIAL; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0031895263     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,246] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
2. Belanger, P., C. C. Nast, R. Fratti, H. Sanati, and M. Ghannoum. 1997. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1840-1842.
3. Berg, J., C. J. Clancy, and M. H. Nguyen. The hidden danger of primary fluconazole prophylaxis in patients with acquired immunodeficiency syndrome. Clin. Infect. Dis., in press.
4. Martin, M. V., J. Yates, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
5. Moskowitz, B. L. 1993. Randomized, comparative study of itraconazole and fluconazole for treatment of AIDS-related cryptococcal meningitis. In Proceedings of the First National Conference on Human Retroviruses and Related Infections, Washington, D.C. (Abstract.)
6. Murphy, M., E. M. Beranard, T. Ishimary, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
7. National Committee for Clinical Laboratory Standards. 1995. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Rex, J. H., M. A. Pfaller, J. N. Galgiani, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin. Infect. Dis. 24:235-247.
9. Ruhnke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577.
10. Saag, M. S., G. C. Cloud, J. R. Graybill, J. Sobel, C. Tuazon, B. Wiesinger, L. Riser, B. L. Moskovitz, W. E. Dismukes, and the NIAID Mycoses Study Group. 1995. Comparison of fluconazole (FLU) versus itraconazole (ITRA) as maintenance therapy of AIDS-associated cryptococcal meningitis (CM), abstr. I218, p. 244. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.